

**ASX RELEASE (ASX: MDR)**

## **MedAdvisor Board evolution and CFO appointment**

- **Anthony Tassone, Victorian Branch President of the Pharmacy Guild of Australia, to be appointed Non-executive Director as a nominee for the Guild Group**
- **Executive Director Josh Swinnerton to retire from the Board and remain as an executive, continuing to provide support and innovation advice across the business**
- **Ancila Desai appointed Chief Financial Officer, bringing more than 20 years' experience in finance leadership roles**

**Melbourne, Australia, 25 July, 2022** – MedTech company, MedAdvisor Limited (**MedAdvisor** or the **Company**) is pleased to announce the following changes to its Board and senior executive team as the Company enters its next growth phase.

### **Anthony Tassone to be appointed Non-executive Director following the acquisition of GuildLink and investment by Guild Group into MedAdvisor**

Following MedAdvisor's agreement to acquire GuildLink Pty Limited (**GuildLink**) and Guild Group Holdings Limited's (**Guild Group's**) investment and resulting substantial holding in MedAdvisor (see separate ASX announcement released today), Anthony Tassone is to be appointed to the Board of MedAdvisor as a nominee for the Guild Group, effective 27 July 2022 (subject to completion of the acquisition).

A community pharmacist and proprietor of community pharmacies for 16 years, Anthony has been the Victorian Branch President of the Pharmacy Guild of Australia (**PGA**) since 2013. In addition he is the National Vice President of Health Economics and Policy for PGA, which leads engagement and negotiation with the Commonwealth Government and Department of Health for five-yearly community pharmacy agreements. His 20-year career in the pharmacy sector encompasses serving on a range of advisory boards for multi-national pharmaceutical companies, and other advisory roles with State and Federal governments.

## **Executive Director Josh Swinnerton to retire from the Board and remain as an executive**

Co-founder and Executive Director Josh Swinnerton has decided to step away from MedAdvisor's board effective 27 July 2022. Josh will remain involved in the organisation in his executive capacity, continuing to provide support and innovation advice across the business. Co-founding MedAdvisor in 2012, Josh was a key member of the team that identified the challenges and opportunities around medication management and adherence. Recently Josh spent several years in the US exploring opportunities that ultimately led to the acquisition and successful integration of Adheris.

"With MedAdvisor well established as a major provider of medication management technology, this is the right time for me to step off the Board. I look forward to continuing to support MedAdvisor on this next phase of growth and am excited by the opportunities I see for the business," said Josh.

## **Ancila Desai appointed Chief Financial Officer**

Effective 17 October 2022, Ancila Desai will become MedAdvisor's Chief Financial Officer (CFO). Currently CFO of life sciences company IDT Australia (ASX:IDT), her more than 20 years' experience in finance leadership roles across multiple sectors including life sciences, FMCG, and logistics with companies including Metcash Limited, Toll Holdings Limited and Hollister Inc, positions her well to support MedAdvisor in this strategic finance role.

## **Commenting on the board changes and CFO appointment, MedAdvisor Chair, Linda Jenkinson, said:**

"Anthony's appointment to the MedAdvisor Board, as nominee of the Guild Group, will further build the Company's deep pharmaceutical expertise and will help guide MedAdvisor to further support pharmacies across Australia to provide better and more efficient services for their customers. We look forward to Anthony joining the Board and working closely with MedAdvisor's Directors to provide counsel and support to our management team to enable delivery of the exciting growth opportunities we see for the business.

"I would like to thank co-founder and Executive Director, Josh Swinnerton, for his tireless service to the Company over the past 10 years. Amongst many achievements, he was instrumental in our acquisition and integration of Adheris in the US. I'm pleased to say he will continue to provide his expertise to the Company via an executive capacity.

“The Company’s senior executive team has also been bolstered with Ancila soon joining us as CFO. She will add to the capabilities of our executive team and alongside Rick Ratliff, further strengthen our ability to execute the next phase of growth and development for MedAdvisor. I also thank in advance Annabelle Grant for undertaking the Acting CFO role in the intervening period and look forward to her continuing support as General Manager Finance.”

- ENDS -

*This document has been authorised for release by the Board.*

**For more information:**

**Company**

Annabelle Grant

Acting CFO

[corporate@medadvisor.com.au](mailto:corporate@medadvisor.com.au)

+61 3 9095 3036

**Investors**

Ronn Bechler

[ronn.bechler@marketeye.com.au](mailto:ronn.bechler@marketeye.com.au)

+61 400 009 774

**Media**

Tristan Everett

[tristan.everett@marketeye.com.au](mailto:tristan.everett@marketeye.com.au)

+61 403 789 096

**About MedAdvisor**

*MedAdvisor is a world-class medication management platform that empowers patients to more simply manage their medication and improve adherence. MedAdvisor’s highly automated and intuitive software system connects patients to tools and education materials from their preferred pharmacy. MedAdvisor works with 25,000 pharmacies in the US to deliver programs to help patients take their medication safely and effectively. In Australia, MedAdvisor has connected over 2.9 million patients through more than 70% of Australian pharmacies. MedAdvisor has partnered with Cotiviti in the US, and is on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: [mymedadvisor.com/investors](http://mymedadvisor.com/investors)*